Regeneus partners with Lonza for manufacturing CryoShotCanine...

Regeneus partners with Lonza for manufacturing CryoShot
Canine cell therapy product for US FDA trial
Sydney, Australia – 22 January 2014

Regenerative medicine company, Regeneus (ASX: RGS), announced today that Lonza, the world’s largest
manufacturer of stem cells will manufacture Regeneus’ off-the-shelf cell therapy, CryoShot® Canine, for
registration in the US.
“It is very exciting to be partnering with Lonza, a global manufacturer with specialist experience in
manufacturing stem cells to the quality standards that the US and European regulators require for product
registration”, said Dr Duncan Thomson, Head of Veterinary Health at Regeneus. “We view this as the start
of a long-term relationship in which Lonza will manufacture CryoShot for the world wide canine market.
Our clinical trial work in Australia has been rewarding and it is now time to begin registration of the
CryoShot product in the US and European markets.”
The cells will be manufactured at the Lonza facility in Walkersville, Maryland and then distributed to the
participating trial veterinarian clinics.
CryoShot Canine is an off-the-shelf allogeneic cell therapy product for the treatment of musculoskeletal
conditions in dogs and is currently under pre-registration trial in Australia. The cell therapy is produced from
a small amount of adipose (fat) tissue derived from a donor animal. The tissue is processed and cultured to
isolate and increase the regenerative cells before being cryogenically frozen and stored in liquid nitrogen.
It is delivered to veterinary clinics cryogenically frozen and then thawed for injection by the treating
veterinarian.
This follows the Regeneus company announcement on 14 November 2013 that Regeneus can proceed
with the commercialisation of its novel canine cancer vaccine in the USA.
END
Media contact:
Clare Serafini
Communications Manager, Regeneus Ltd
T: +61 2 9499 8010
M: +61 (0)417 299 081
E: [email protected] or visit: www.regeneus.com.au
Investor contact: